Ipsen Biopharmaceuticals implements enhanced patient support program

Program Provides Coverage, Access, Reimbursement, & Education Support Regarding Ipsen Medicines to Patients and their Healthcare Providers

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the implementation of IPSEN CARES^TM (Coverage, Access, Reimbursement, & Education Support). Ensuring patients, providers and caregivers have the resources needed to help access the Ipsen medications that are critical to managing their conditions, IPSEN CARES is staffed Monday to Friday by experts who can assist with a broad range of medical, educational, logistical and coverage information regarding Ipsen medicines, including Increlex^® (mecasermin), Somatuline^® Depot^® (lanreotide), and Dysport^® (abobotulinumtoxinA).

“At Ipsen, improving the lives of patients is what drives us each and every day,” said Cynthia Schwalm, President and CEO, Ipsen N.A. “We are committed to providing information and support to our patients to help them access, receive and properly use our medications.

Involving the entire treatment team that surrounds patients on a daily basis, IPSEN CARES can provide benefits verification (research of a patient’s medical or pharmacy benefit insurance coverage); prior authorization information; a patient assistance program (free medications for uninsured patients); co-pay assistance programs; billing and coding support; coordination with specialty pharmacies; injection training and adherence calls.